This study is the first to suggest neuroendocrine differentiation in a small subset of ameloblastomas, characterized by SYP positivity and CgA negativity, along with INSM1 immunoexpression, in line with the recent understanding of neuroendocrine characteristics in the WHO classification. The gene discussed is INSM1; the disease is ameloblastoma.